Hikma Pharmaceuticals PLC (LON:HIK)
1,650.00
+6.00 (0.36%)
Nov 12, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Employees
Hikma Pharmaceuticals had 9,500 employees as of June 30, 2026. The number of employees increased by 100 or 1.06% since the number was reported on December 31, 2025. That makes Hikma Pharmaceuticals the 3,472nd largest employer in the world and 114th in the United Kingdom.
Employees
9,500
Change
100
Growth
1.06%
Revenue / Employee
271.25K GBP
Profits / Employee
30.70K GBP
Market Cap
3.42B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 9,500 | 100 | 1.06% |
| Dec 31, 2025 | 9,400 | -100 | -1.05% |
| Dec 31, 2024 | 9,500 | 400 | 4.40% |
| Dec 31, 2023 | 9,100 | 300 | 3.41% |
| Dec 31, 2022 | 8,800 | 100 | 1.15% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| HUTCHMED (China) | 1,790 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 213 |
| Shield Therapeutics | 61 |
| Chill Brands Group | 11 |
| Provexis | 2 |
Hikma Pharmaceuticals News
- 7 days ago - Hikma Pharmaceuticals Raises Profit Floor as Branded Growth Offsets Injectables Slowdown - MarketBeat
- 7 days ago - Hikma Pharmaceuticals Transcript: Trading update - Transcripts
- 7 days ago - Hikma Pharmaceuticals Earnings release: Trading update - Filings
- 7 days ago - Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance - Nasdaq
- 7 days ago - UK's Hikma tightens annual profit outlook as branded medicines drive growth - Reuters
- 17 days ago - Hikma Pharmaceuticals PLC - Depositary Receipt Price Target Decreased by 17.53% to $51.72 - Nasdaq
- 23 days ago - Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress - MarketBeat
- 23 days ago - Hikma Pharmaceuticals Transcript: Investor update - Transcripts